Study: Anti-microRNA drug significantly reduces miR-92a levels in human peripheral blood

A solitary intravenous dose of MRG-110, an anti-microRNA drug, appreciably lowered miR-92a degrees in the blood of nutritious human beings.

Inhibition of miR-92a has demonstrated useful consequences in animal products, like enhanced vascularization just after myocardial infarction, and accelerated wound therapeutic, in accordance to the peer-reviewed journal Nucleic Acid Therapeutics.

“Dependent on documented, promising therapeutic opportunity, locked nucleic acid (LNA)-based mostly anti-miR-92a was more produced and examined in a initial in human examine,” claimed Stefanie Dimmeler, PhD, Goethe College, Frankfurt, Germany and coauthors. “MRG-110 brought on de-repression of gene targets in human peripheral blood cells.”

This is an essential randomized, double-blind, placebo-managed, dose-escalating examine translating preceding function on systemically sent LNA-modified anti-miR oligonucleotide compounds to effectively lessen miR-92a degrees in human peripheral blood,”

Graham C. Parker, PhD, Govt Editor, The Carman and Ann Adams Section of Pediatrics, Wayne Point out College College of Medication, Kid’s Healthcare facility of Michigan, Detroit, MI

Journal reference:

Abplanalp, W. T., et al. (2020) Effectiveness and Focus on Derepression of Anti-miR-92a: Success of a To start with in Human Analyze. Nucleic Acid Therapeutics.

Children's Health

Articles You May Like

The US remains a grim leader in preterm births. Why? And can we fix it?
COVID-19 pandemic left high school students sleep-deprived and struggling with mental health
Childhood and adolescent obesity: time to act
Food FARMacia program associated with reduced food insecurity and obesity in children
The Best Lunch Boxes For Kids, According To Reviews